Neurology | Phase II Developments | SWITZERLAND

Addex Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study

Lead Product(s): ADX71149

Therapeutic Area: Neurology Product Name: JNJ-40411813

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2020

Details:

The multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam.

Novaremed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Novaremed Submits IND to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy

Lead Product(s): NRD135S.E1

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2020

Details:

The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients with neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once daily for 3 months.

Oculis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery

Lead Product(s): Dexamethasone

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 07, 2020

Details:

Presentation will highlight results from Oculis's Phase 2 clinical trial, assessing the safety & efficacy of its drug candidate OCS-01 for the treatment of inflammation & pain after cataract surgery.

GeNeuro

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

GeNeuro Announces Successful €17.5 Million Private Placement

Lead Product(s): Temelimab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Bryan, Garnier & Co

Deal Size: $19.3 million Upfront Cash: Undisclosed

Deal Type: Investment January 31, 2020

Details:

Successfully completing this private placement provides GeNeuro the means to complete the planned study of temelimab in multiple sclerosis patients with disability progression without relapses.

Find

Find Neurology Drugs in Phase II Clinical Development in SWITZERLAND

Switzerland

Product Type

Companies

Addex Therapeutics

Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study

Novaremed

Novaremed Submits IND to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy

Oculis

Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery

GeNeuro

GeNeuro Announces Successful €17.5 Million Private Placement